About Menten AI
Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.
Company details
Funding
Total raised
$4.2M
Last stage
Seed
Investors
Founders
Hans Melo
PhD in Machine Learning and Computational Neuroscience. Co-founded Menten AI with Tamas Gorbe and Vikram Mulligan. Background in quantum computing and machine learning applied to drug discovery.
LinkedInTamás Görbe
PhD in Biocatalysis, Protein Engineering, and Medicinal Chemistry. Co-founder responsible for chemistry and enzymatic applications at Menten AI.
Vikram K. Mulligan
PhD and protein design expert; core developer of the Rosetta software suite and researcher from the Flatiron Institute focused on computational biology.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.
